Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liver Neoplasms: early-phase trial registry
4 of 15 indexed Liver Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 4 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Liver Neoplasms: 15 US clinical trials tracked, 4 recruiting.
Liver Neoplasms is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is HistoSonics, running 2 of these trials.
Enrollment posture brief
Registry condition liver-neoplasms
OPEN 4 | RECR 27% | LATE 1 | EARLY 12 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)
Liver Neoplasms lists 4 open slots (27% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liver Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liver Neoplasms is recruiting below its size-band peers.
4 of 15 indexed trials (26.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Liver Neoplasms trials is spread across many organizations.
HistoSonics accounts for 2 of 15 trials (13.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Liver Neoplasms trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Liver Neoplasms research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
HistoSonics
NCT06486454
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
john eisenbrey
NCT06261814
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
UNC Lineberger Comprehensive Cancer Center
NCT07225114
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Eureka Therapeutics
NCT04634357
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai
NCT04008797
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
HistoSonics
NCT04572633
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
Bracco Diagnostics
NCT00788697
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
NCT01033240
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
H3 Biomedicine
NCT02834780
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
Southwestern Regional Medical Center
NCT00493883
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
MediGene
NCT00149396
Sorafenib and TRC105 in Hepatocellular Cancer
National Cancer Institute (NCI)
NCT01306058
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Masonic Cancer Center, University of Minnesota
NCT01099631
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
National Cancer Institute (NCI)
NCT00081848
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Anza Therapeutics
NCT00327652
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Liver Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liver Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liver Neoplasms page
15 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Liver Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- HistoSonics sponsors the most Liver Neoplasms trials on record, review their full trial history before evaluating a specific study. See HistoSonics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Neoplasms condition card totals 15 registered trials; most-linked intervention Sorafenib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.